TechnoVax
Biotechnology Research • 
Elmsford, New York, United States • 1-10 Employees
Company overview
| Headquarters | Elmsford, New York, United States |
| Phone number | +1914345230010 |
| Website | |
| SIC | 283 |
| Keywords | Biotechnology, HIV, Cancer, PIV, Influenza, Vaccine, Bio-Services, RSV, Virus-Like Particle, VLP, Covid-19 |
| Founded | 2003 |
| Employees | 1-10 |
| Socials |
Key Contact at TechnoVax
Jose M. Galarza
CEO, Founder
TechnoVax Email Formats
TechnoVax uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@technovax.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@technovax.com | 60% |
{first initial}{last name} | jdoe@technovax.com | 40% |
About TechnoVax
TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.
TechnoVax revenue & valuation
| Annual revenue | $10,500,000 |
| Revenue per employee | $2,085,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $33,400,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
TechnoVax has 1 employees across 1 departments.
Departments
Number of employees
TechnoVax Tech Stack
Discover the technologies and tools that power TechnoVax's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Security
Ecommerce
Security
Miscellaneous
JavaScript libraries
JavaScript libraries
Maps
CMS
Netherlands
United Kingdom
Spain
Frequently asked questions
4.8
40,000 users
